A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at
multiple clinical centers. The study is designed to determine the safety, tolerability and PK
of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to
standard therapy or for whom there is no standard therapy. After the determination of the
maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with
refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) tumors.